Involvement of non-dopaminergic pathways in Parkinson's disease : Pathophysiology and therapeutic implications
Identifieur interne : 000045 ( PascalFrancis/Curation ); précédent : 000044; suivant : 000046Involvement of non-dopaminergic pathways in Parkinson's disease : Pathophysiology and therapeutic implications
Auteurs : A.-M. Bonnet [France]Source :
- CNS drugs [ 1172-7047 ] ; 2000.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Parkinson's disease is primarily characterised by degeneration of the nigrostriatal dopaminergic pathways in the basal ganglia. However, non-dopaminergic neurotransmission is also affected in Parkinson's disease. The dysfunction of non-dopaminergic systems explains the principal non-dopaminergic symptoms, such as axial' signs and cognitive impairment. The non-dopaminergic neurotransmitters affected in Parkinson's disease are noradrenaline (norepinephrine), serotonin (5-hydroxytryptamine; 5-HT), glutamate, γ-aminobutyric acid (GABA), acetylcholine and neuropeptides. Dysfunction of these systems can lead to some of the motor symptoms of the disease and may provide targets for pharmacological interventions to treat these symptoms. For example, antagonists of certain glutamate receptors have been found to improve parkinsonian symptoms when given in associated with levodopa, although adverse effects may limit their use. The dysfunction of non-doparninergic neurotransmitter systems in Parkinson's disease is also important because it can lead to non-motor symptoms that are not responsive to dopaminergic therapy and can be a major cause of disability during disease evolution. Dysautonomia is not infrequent in individuals with Parkinson's disease and is characterised by constipation, urinary disorders and orthostatic hypotension, the latter resulting from deficits in adrenergic and noradrenergic neurotransmission. Postural instability is caused by abnormalities in both dopaminergic and non-dopaminergic pathways. Depression is partially a result of dopaminergic denervation, but also of a decrease of serotonergic transmission. Cognitive impairment with frontal lobe-like symptomatology is a result of the dopaminergic deficit but also, at least in part, a cholinergic and noradrenergic deficit. Long term use of levodopa can be associated with complications such as dyskinesias. Although these are treated initially with other dopaminergic treatments, including changes in the levodopa administration schedule and dopamine receptor agonists, there have been attempts to treat dyskinesias with non-dopaminergic drugs. Agents such as glutamate antagonists and opioid antagonists have been found to be useful.
pA |
|
---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001393
Links to Exploration step
Pascal:00-0242418Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Involvement of non-dopaminergic pathways in Parkinson's disease : Pathophysiology and therapeutic implications</title>
<author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A.-M." last="Bonnet">A.-M. Bonnet</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Fédération de Neurologie Y Agid MD and O Lyon-Caen MD, Hopital Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0242418</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0242418 INIST</idno>
<idno type="RBID">Pascal:00-0242418</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001393</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000045</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Involvement of non-dopaminergic pathways in Parkinson's disease : Pathophysiology and therapeutic implications</title>
<author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A.-M." last="Bonnet">A.-M. Bonnet</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Fédération de Neurologie Y Agid MD and O Lyon-Caen MD, Hopital Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">CNS drugs</title>
<title level="j" type="abbreviated">CNS drugs</title>
<idno type="ISSN">1172-7047</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">CNS drugs</title>
<title level="j" type="abbreviated">CNS drugs</title>
<idno type="ISSN">1172-7047</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetylcholine</term>
<term>Antiparkinson agent</term>
<term>Basal ganglion</term>
<term>Brain (vertebrata)</term>
<term>Catecholamine</term>
<term>Central nervous system</term>
<term>Chemotherapy</term>
<term>Dopamine</term>
<term>GABA</term>
<term>Glutamate</term>
<term>Human</term>
<term>Levodopa</term>
<term>Long term</term>
<term>Neuropeptide</term>
<term>Parkinson disease</term>
<term>Pathogenesis</term>
<term>Review</term>
<term>Serotonin</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Homme</term>
<term>Pathogénie</term>
<term>Article synthèse</term>
<term>Traitement</term>
<term>Chimiothérapie</term>
<term>Long terme</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Toxicité</term>
<term>Noyau gris central</term>
<term>Encéphale</term>
<term>Système nerveux central</term>
<term>Neuropeptide</term>
<term>Catécholamine</term>
<term>Sérotonine</term>
<term>Glutamate</term>
<term>Dopamine</term>
<term>GABA</term>
<term>Acétylcholine</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Parkinson's disease is primarily characterised by degeneration of the nigrostriatal dopaminergic pathways in the basal ganglia. However, non-dopaminergic neurotransmission is also affected in Parkinson's disease. The dysfunction of non-dopaminergic systems explains the principal non-dopaminergic symptoms, such as axial' signs and cognitive impairment. The non-dopaminergic neurotransmitters affected in Parkinson's disease are noradrenaline (norepinephrine), serotonin (5-hydroxytryptamine; 5-HT), glutamate, γ-aminobutyric acid (GABA), acetylcholine and neuropeptides. Dysfunction of these systems can lead to some of the motor symptoms of the disease and may provide targets for pharmacological interventions to treat these symptoms. For example, antagonists of certain glutamate receptors have been found to improve parkinsonian symptoms when given in associated with levodopa, although adverse effects may limit their use. The dysfunction of non-doparninergic neurotransmitter systems in Parkinson's disease is also important because it can lead to non-motor symptoms that are not responsive to dopaminergic therapy and can be a major cause of disability during disease evolution. Dysautonomia is not infrequent in individuals with Parkinson's disease and is characterised by constipation, urinary disorders and orthostatic hypotension, the latter resulting from deficits in adrenergic and noradrenergic neurotransmission. Postural instability is caused by abnormalities in both dopaminergic and non-dopaminergic pathways. Depression is partially a result of dopaminergic denervation, but also of a decrease of serotonergic transmission. Cognitive impairment with frontal lobe-like symptomatology is a result of the dopaminergic deficit but also, at least in part, a cholinergic and noradrenergic deficit. Long term use of levodopa can be associated with complications such as dyskinesias. Although these are treated initially with other dopaminergic treatments, including changes in the levodopa administration schedule and dopamine receptor agonists, there have been attempts to treat dyskinesias with non-dopaminergic drugs. Agents such as glutamate antagonists and opioid antagonists have been found to be useful.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1172-7047</s0>
</fA01>
<fA03 i2="1"><s0>CNS drugs</s0>
</fA03>
<fA05><s2>13</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Involvement of non-dopaminergic pathways in Parkinson's disease : Pathophysiology and therapeutic implications</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BONNET (A.-M.)</s1>
</fA11>
<fA14 i1="01"><s1>Fédération de Neurologie Y Agid MD and O Lyon-Caen MD, Hopital Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA20><s1>351-364</s1>
</fA20>
<fA21><s1>2000</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>26528</s2>
<s5>354000086516490050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2000 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>119 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>00-0242418</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>CNS drugs</s0>
</fA64>
<fA66 i1="01"><s0>NZL</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Parkinson's disease is primarily characterised by degeneration of the nigrostriatal dopaminergic pathways in the basal ganglia. However, non-dopaminergic neurotransmission is also affected in Parkinson's disease. The dysfunction of non-dopaminergic systems explains the principal non-dopaminergic symptoms, such as axial' signs and cognitive impairment. The non-dopaminergic neurotransmitters affected in Parkinson's disease are noradrenaline (norepinephrine), serotonin (5-hydroxytryptamine; 5-HT), glutamate, γ-aminobutyric acid (GABA), acetylcholine and neuropeptides. Dysfunction of these systems can lead to some of the motor symptoms of the disease and may provide targets for pharmacological interventions to treat these symptoms. For example, antagonists of certain glutamate receptors have been found to improve parkinsonian symptoms when given in associated with levodopa, although adverse effects may limit their use. The dysfunction of non-doparninergic neurotransmitter systems in Parkinson's disease is also important because it can lead to non-motor symptoms that are not responsive to dopaminergic therapy and can be a major cause of disability during disease evolution. Dysautonomia is not infrequent in individuals with Parkinson's disease and is characterised by constipation, urinary disorders and orthostatic hypotension, the latter resulting from deficits in adrenergic and noradrenergic neurotransmission. Postural instability is caused by abnormalities in both dopaminergic and non-dopaminergic pathways. Depression is partially a result of dopaminergic denervation, but also of a decrease of serotonergic transmission. Cognitive impairment with frontal lobe-like symptomatology is a result of the dopaminergic deficit but also, at least in part, a cholinergic and noradrenergic deficit. Long term use of levodopa can be associated with complications such as dyskinesias. Although these are treated initially with other dopaminergic treatments, including changes in the levodopa administration schedule and dopamine receptor agonists, there have been attempts to treat dyskinesias with non-dopaminergic drugs. Agents such as glutamate antagonists and opioid antagonists have been found to be useful.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Homme</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Human</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Hombre</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathogénie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Pathogenesis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Patogenia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Review</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Traitement</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Treatment</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Long terme</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Long term</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>15</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Noyau gris central</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Basal ganglion</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Núcleo basal</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Brain (vertebrata)</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Neuropeptide</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Neuropeptide</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Neuropéptido</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Sérotonine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Serotonin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Serotonina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>21</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Glutamate</s0>
<s2>NK</s2>
<s2>FX</s2>
<s5>22</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Glutamate</s0>
<s2>NK</s2>
<s2>FX</s2>
<s5>22</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Glutamato</s0>
<s2>NK</s2>
<s2>FX</s2>
<s5>22</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>23</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>23</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>23</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>GABA</s0>
<s2>NK</s2>
<s5>24</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG"><s0>GABA</s0>
<s2>NK</s2>
<s5>24</s5>
</fC03>
<fC03 i1="19" i2="X" l="SPA"><s0>GABA</s0>
<s2>NK</s2>
<s5>24</s5>
</fC03>
<fC03 i1="20" i2="X" l="FRE"><s0>Acétylcholine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>35</s5>
</fC03>
<fC03 i1="20" i2="X" l="ENG"><s0>Acetylcholine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>35</s5>
</fC03>
<fC03 i1="20" i2="X" l="SPA"><s0>Acetilcolina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>35</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21><s1>164</s1>
</fN21>
</pA>
</standard>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000045 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000045 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PascalFrancis |étape= Curation |type= RBID |clé= Pascal:00-0242418 |texte= Involvement of non-dopaminergic pathways in Parkinson's disease : Pathophysiology and therapeutic implications }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |